Examining how asthma affects brain function and mental health

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the impact of asthma on brain function by comparing microglial activation in individuals with severe asthma to healthy controls. Participants will undergo a series of assessments including questionnaires, computer tasks, allergy skin tests, breathing tests, blood samples, sputum samples, and brain imaging scans using PET/MRI technology. The study seeks to understand the relationship between airway inflammation in asthma and symptoms of depression and anxiety. By analyzing these factors, researchers hope to gain insights into the neurological effects of asthma.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Ability to understand and the willingness to sign a written informed consent document
* Individuals with no health concerns that might affect the outcome of the study
* Age 18-75 years of age
* Ability to tolerate a simulated MRI brain scanning session
* In the opinion of the investigator, capable and willing to grant written informed consent and cooperate with study procedures and requirements
* High-affinity TSPO-binding genotype. Mixed (high/low) binding-affinity genotype may be included at PIs discretion
* For participants with severe asthma:

  * Physician diagnosis of asthma for at least six months prior to screening (can be determined at the discretion of an asthma/allergy physician member of the study team)
  * Severe asthmatics must meet the ATS definition of severe asthma and/or be currently receiving a GINA Step 4 or 5 therapy or daily treatment of 320mcg budesonide. Therapy may include ongoing use of currently approved biologic immunomodulators

Exclusion Criteria:

* Current smoker (defined as more than 0.5 pack per week for the past 6 months and any smoking within two weeks of study procedures) or has a smoking history exceeding 5 pack years within the last 10 years
* Currently receiving allergen immunotherapy unless on stable dose.
* Use of psychotropic medication that might affect function of neurocircuitry implicated in our hypotheses (at the discretion of the PI/Co-I)
* Inability to hold medications detailed in the medication hold schedule
* Needle phobia or claustrophobia
* Major health problems such any of the following in the last 6 months: stroke/TIA, myocardial Infarction, stent placement, or acute coronary syndrome are definitively exclusionary. Decisions regarding other major health problems, such as autoimmune disease, history of carotid stenosis, heart disease, uncontrolled hypertension, lung diseases other than asthma, history of significant arrhythmias, etc. will be based upon the judgement of the PI/Co-I.
* Use of biologic medication that might affect signaling pathways under investigation (at the discretion of the PI/Co-I)
* Pre-existing chronic infectious disease
* Scheduled use of non-selective beta-blockers prior to each study visit.
* Use of an investigational drug within 30 days of entering the study. This criterion will be reviewed on a case by case basis by the PI/Co-I to determine appropriate washout period. Appropriate wash out period may be greater than 30 days depending on the half-life of the investigational drug. Participants may be eligible for study participation after completing the washout period designated by the PI or Co-I (physician only).
* Any MRI incompatibility as determined by most current MRI screening form
* History of a diagnosed bipolar disorder, schizophrenia, or schizoaffective disorder
* History of serious head trauma or seizure disorder (can be included at the discretion of the PI or Co-I)
* Unable, in the judgement of the investigator, to comply with directions and/or tolerate the procedures required for participation in this study
* Pregnant or breast-feeding or has a planned pregnancy during the course of the study
* Any other medical condition or disease that would impact participant safety or data integrity in the opinion of the PI/CO-I

Where it's running

• Center for Healthy Minds
  Madison, Wisconsin, United States Recruiting

Study contacts

• Principal investigator: Melissa Rosenkranz, PhD — University of Wisconsin, Madison
• Study coordinator: Rachel Kaspari
• Email: maia@medicine.wisc.edu
• Phone: 608-263-0524

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Chronic Respiratory Disease Participant Engagement

  This study tests whether adults with long-term lung conditions can get comfortable with a clinical trials unit and research team before joining future trials.

  Recruiting Richmond Pharmacology Limited · London · NCT07924462

• HB0056 in adults with moderate to severe asthma

  This study tests HB0056 versus a placebo to see if it helps adults with moderate to severe asthma reduce rescue inhaler use and improve symptoms.

  Recruiting at 2 sites Phase 1/2 Shanghai Huaota Biopharmaceutical Co., Ltd. · Beijing and 1 other locations · NCT07899996

• Tilrekimig (PF-07275315) for Severe Asthma: Aimed at Adults with Frequent Exacerbations

  This study tests whether tilrekimig helps people with severe asthma who have had multiple flare-ups in the past year, by comparing it to a placebo given every four weeks.

  Recruiting at 4 sites Phase 3 Pfizer · River Forest, Illinois and 11 other locations · NCT07869043

• Inhaled CHF10136 safety and pharmacokinetics in healthy adults and adults with asthma

  This first-in-human study tests inhaled CHF10136 to see if it is safe and well tolerated, how it behaves in the body, and how it affects adults with asthma compared with placebo.

  Recruiting Phase 1 Chiesi Farmaceutici S.p.A. · Leeds and 2 other locations · NCT07851623

• Biologics for Type 2 Inflammation in Asthma and COPD in Real World

  This real-world study tests whether six biologic drugs can reduce flare-ups and improve symptoms in adults with asthma or COPD treated in routine care in China.

  Recruiting Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07823842

• GSK5784283 vs placebo in uncontrolled asthma (PERSIST ASTHMA-2)

  A new medicine called GSK5784283 is being tested to see if it lowers asthma flare-ups better than a placebo in people with uncontrolled asthma.

  Recruiting at 7 sites Phase 3 GlaxoSmithKline · San Diego, California and 6 other locations · NCT07782996

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.